Patents by Inventor Christopher H. Taron

Christopher H. Taron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8486660
    Abstract: Methods and compositions are described that relate to obtaining concentrated preparations of secreted recombinant proteins. These proteins are expressed in the form of fusion proteins with a chitin-binding domain (CBD). The fusion proteins are capable of being concentrated in the presence of chitin. Also described is: a shuttle vector that includes a modified LAC4 promoter; a chitinase-negative host cell; a CBD capable of eluting from chitin under non-denaturing conditions; and sterilized chitin, which can be optionally magnetized for facilitating recovery of recombinant protein.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: July 16, 2013
    Assignee: New England Biolabs, Inc.
    Inventors: Christopher H. Taron, Paul A. Colussi
  • Patent number: 8361750
    Abstract: A recombinant BSA (rBSA) that (a) substantially lacks deoxyribonuclease activity as determined by incubating rBSA with linear DNA overnight and gel electrophoresis, (b) lacks animal viruses associated with animal-derived cell growth supplements; and (c) is capable of stabilizing DNA proteins is provided. Methods for making the rBSA and using it to stabilize enzymes are also provided.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: January 29, 2013
    Assignee: New England Biolabs, Inc.
    Inventors: Paul A. Colussi, Thomas C. Evans, Jr., Christopher H. Taron
  • Patent number: 8288337
    Abstract: Compositions and methods are provided for creating and identifying mutant carbohydrate-binding proteins that reversibly bind to carbohydrate substrates under conditions where the native protein remains bound. Examples of modified chitin-binding domains are provided which can be eluted from chitin in the presence of a reducing agent or at a pH within the range of 5-10.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: October 16, 2012
    Assignee: New England Biolabs, Inc.
    Inventors: Christopher H. Taron, Paul A. Colussi, Jeremiah Read
  • Publication number: 20120107877
    Abstract: Methods and compositions are described that relate to obtaining concentrated preparations of secreted recombinant proteins. These proteins are expressed in the form of fusion proteins with a chitin-binding domain (CBD). The fusion proteins are capable of being concentrated in the presence of chitin. Also described is: a shuttle vector that includes a modified LAC4 promoter; a chitinase-negative host cell; a CBD capable of eluting from chitin under non-denaturing conditions; and sterilized chitin, which can be optionally magnetized for facilitating recovery of recombinant protein.
    Type: Application
    Filed: January 9, 2012
    Publication date: May 3, 2012
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventors: Christopher H. Taron, Paul A. Colussi
  • Patent number: 8119390
    Abstract: Methods and compositions are described that relate to obtaining concentrated preparations of secreted recombinant proteins. These proteins are expressed in the form of fusion proteins with a chitin-binding domain (CBD). The fusion proteins are capable of being concentrated in the presence of chitin. Also described is: a shuttle vector that includes a modified LAC4 promoter; a chitinase-negative host cell; a CBD capable of eluting from chitin under non-denaturing conditions; and sterilized chitin, which can be optionally magnetized for facilitating recovery of recombinant protein.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: February 21, 2012
    Assignee: New England Biolabs, Inc.
    Inventors: Christopher H. Taron, Paul A. Colussi
  • Publication number: 20120028305
    Abstract: Methods and compositions are provided that relate to a composition that includes a modified maltose-binding protein (MBP) which when fused to a protein results in an increase in binding affinity for maltodextrin compared with the wild type MBP fused to the protein, the modified MBP maintaining enhanced solubility, The modification includes a mutation selected from the group consisting of: F68L, I318V, Q326R, V344M, and T372TTTITITTTLGIEGR387 or consist of two or more mutations selected from the group consisting of: F68L, S146T, A313V, I318V, I318A, Q326R, V344M and T372TTTITITTTLGIEGR387 mutants.
    Type: Application
    Filed: April 1, 2009
    Publication date: February 2, 2012
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventors: Paul Riggs, Iris Walker, Paul A. Colussi, Mehul Ganatra, Christopher H. Taron
  • Publication number: 20110269202
    Abstract: Compositions and methods are provided for generating biofuels by fermentation from carbon sources other than glucose using genetically engineered yeast strains. For example, a Saccharomyces strain which is capable of converting glucose to ethanol but not of metabolizing N-acetyl glucosamine is genetically engineered to utilize N-acetyl glucosamine as a nutrient carbon source.
    Type: Application
    Filed: November 16, 2009
    Publication date: November 3, 2011
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventors: Christopher H. Taron, Paul A. Colussi
  • Publication number: 20110071280
    Abstract: Methods and compositions are described that relate to obtaining concentrated preparations of secreted recombinant proteins. These proteins are expressed in the form of fusion proteins with a chitin-binding domain (CBD). The fusion proteins are capable of being concentrated in the presence of chitin. Also described is: a shuttle vector that includes a modified LAC4 promoter; a chitinase-negative host cell; a CBD capable of eluting from chitin under non-denaturing conditions; and sterilized chitin, which can be optionally magnetized for facilitating recovery of recombinant protein.
    Type: Application
    Filed: March 6, 2009
    Publication date: March 24, 2011
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventors: Christopher H. Taron, Paul A. Colussi
  • Patent number: 7883867
    Abstract: Methods and compositions are provided for increasing at least one of: (i) binding affinity of a target protein for a maltodextrin substrate and/or (ii) solubility of a target protein. The methods and compositions relate to a modified maltose-binding protein.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: February 8, 2011
    Assignee: New England Biolabs, Inc.
    Inventors: Paul Riggs, Pei-Chung Hsieh, Iris Walker, Paul A. Colussi, Mehul Ganatra, Christopher H. Taron
  • Publication number: 20110020911
    Abstract: Methods and compositions are provided for increasing at least one of: (i) binding affinity of a target protein for a maltodextrin substrate and/or (ii) solubility of a target protein. The methods and compositions relate to a modified maltose-binding protein.
    Type: Application
    Filed: August 16, 2010
    Publication date: January 27, 2011
    Applicant: New England Biolabs, Inc.
    Inventors: Paul Riggs, Pei-Chung Hsieh, Iris Walker, Paul A. Colussi, Mehul Ganatra, Christopher H. Taron
  • Patent number: 7825218
    Abstract: Methods and compositions are provided for increasing at least one of: (i) binding affinity of a target protein for a maltodextrin substrate and/or (ii) solubility of a target protein. The methods and compositions relate to a modified maltose-binding protein.
    Type: Grant
    Filed: April 14, 2007
    Date of Patent: November 2, 2010
    Assignee: New England Biolabs, Inc.
    Inventors: Paul Riggs, Pei-Chung Hsieh, Iris Walker, Paul A. Colussi, Mehul Ganatra, Christopher H. Taron
  • Publication number: 20100240099
    Abstract: A recombinant BSA (rBSA) that (a) substantially lacks deoxyribonuclease activity as determined by incubating rBSA with linear DNA overnight and gel electrophoresis, (b) lacks animal viruses associated with animal-derived cell growth supplements; and (c) is capable of stabilizing DNA proteins is provided. Methods for making the rBSA and using it to stabilize enzymes are also provided.
    Type: Application
    Filed: March 30, 2007
    Publication date: September 23, 2010
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventors: Paul A. Colussi, Thomas C. Evans, JR., Christopher H. Taron
  • Patent number: 7732565
    Abstract: Compositions and methods are provided for creating and identifying mutant carbohydrate-binding proteins that reversibly bind to carbohydrate substrates under conditions where the native protein remains bound. Examples of modified chitin-binding domains are provided which can be eluted from chitin in the presence of a reducing agent or at a pH within the range of 5-10.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: June 8, 2010
    Assignee: New England Biolabs, Inc.
    Inventors: Christopher H. Taron, Paul A. Colussi, Jeremiah Read
  • Publication number: 20090305342
    Abstract: Methods and compositions are provided for increasing at least one of: (i) binding affinity of a target protein for a maltodextrin substrate and/or (ii) solubility of a target protein. The methods and compositions relate to a modified maltose-binding protein.
    Type: Application
    Filed: April 14, 2007
    Publication date: December 10, 2009
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventors: Paul Riggs, Pei-Chung Hsieh, Iris Walker, Paul A. Colussi, Mehul Ganatra, Christopher H. Taron
  • Publication number: 20090247423
    Abstract: Compositions and methods are provided for creating and identifying mutant carbohydrate-binding proteins that reversibly bind to carbohydrate substrates under conditions where the native protein remains bound. Examples of modified chitin-binding domains are provided which can be eluted from chitin in the presence of a reducing agent or at a pH within the range of 5-10.
    Type: Application
    Filed: March 6, 2009
    Publication date: October 1, 2009
    Inventors: Christopher H. Taron, Paul A. Colussi, Jeremiah Read
  • Patent number: 7517671
    Abstract: Methods and compositions are described that relate to obtaining concentrated preparations of secreted recombinant proteins. These proteins are expressed in the form of fusion proteins with a chitin-binding domain (CBD). The fusion proteins are capable of being concentrated in the presence of chitin. Also described is: a shuttle vector that includes a modified LAC4 promoter; a chitinase-negative host cell; a CBD capable of eluting from chitin under non-denaturing conditions; and sterilized chitin, which can be optionally magnetized for facilitating recovery of recombinant protein.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: April 14, 2009
    Assignee: New England Biolabs, Inc.
    Inventors: Christopher H. Taron, Paul A. Colussi
  • Patent number: 7094563
    Abstract: Substantially pure glycosidases capable for cleaving selected glycosidic bonds have been described including glycosidases isolated from Xanthomonas and recombinant glycosidases. Substrate specificity of isolated enzymes have been identified for GlcNac?1-x, Gal?1-3R, Gal?1-6R, Gal?1-3R, Fuc?-2R, Fuc?1-3R, Fuc?1-4R, Man?1-2R, Man?1-3R, Man?1-6R, Man?1-4R, Xyl?1-2R, Glc?1-4R, and Gal?1-4R providing improved capability for selectively cleaving a glycosidic linkage in a carbohydrate substrate and for forming modified carbohydrates.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: August 22, 2006
    Assignee: New England Biolabs, Inc.
    Inventors: Sharon T. Wong-Madden, Ellen P. Guthrie, David Landry, Christopher H. Taron, Chudi Guan, Phillips W. Robbins
  • Patent number: 7060465
    Abstract: Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: June 13, 2006
    Assignee: New England Biolabs, Inc.
    Inventors: Ming-qun Xu, Sebastien M. Ferrandon, Christopher H. Taron, Paul A. Colussi
  • Patent number: 6897285
    Abstract: Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: May 24, 2005
    Assignee: New England Biolabs, Inc.
    Inventors: Ming-Qun Xu, Sebastien M. Ferrandon, Christopher H. Taron, Paul A. Colussi
  • Publication number: 20030216550
    Abstract: Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.
    Type: Application
    Filed: February 26, 2003
    Publication date: November 20, 2003
    Applicant: New England Biolabs, Inc.
    Inventors: Ming-Qun Xu, Sebastien M. Ferrandon, Christopher H. Taron, Paul A. Colussi